Hepatopulmonary syndrome medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 13: | Line 13: | ||
*[[Liver transplantation|Orthotopic liver transplantation]] is the only available treatment for patients with hepatopulmonary syndrome. | *[[Liver transplantation|Orthotopic liver transplantation]] is the only available treatment for patients with hepatopulmonary syndrome. | ||
*Supportive therapy for hepatopulmonary syndrome includes [[oxygen therapy]]. | *Supportive therapy for hepatopulmonary syndrome includes [[oxygen therapy]]. | ||
*Nevertheless, norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as standard treatment for HPS.<ref name="pmid20816858">Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20816858 Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.] ''Clin Gastroenterol Hepatol'' 8 (12):1095-8. [http://dx.doi.org/10.1016/j.cgh.2010.08.011 DOI:10.1016/j.cgh.2010.08.011] PMID: [https://pubmed.gov/20816858 20816858]</ref><ref name="pmid18779471">Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18779471 Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.] ''Arch Intern Med'' 168 (16):1820-3. [http://dx.doi.org/10.1001/archinte.168.16.1820 DOI:10.1001/archinte.168.16.1820] PMID: [https://pubmed.gov/18779471 18779471]</ref><ref name="pmid18668653">Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18668653 Pilot study of pentoxifylline in hepatopulmonary syndrome.] ''Liver Transpl'' 14 (8):1199-203. [http://dx.doi.org/10.1002/lt.21482 DOI:10.1002/lt.21482] PMID: [https://pubmed.gov/18668653 18668653]</ref><ref name="pmid12853200">Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G (2003) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12853200 Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome.] ''Lancet'' 362 (9377):43-4. [http://dx.doi.org/10.1016/S0140-6736(03)13807-X DOI:10.1016/S0140-6736(03)13807-X] PMID: [https://pubmed.gov/12853200 12853200]</ref><ref name="pmid11074903">Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C (2000) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11074903 Methylene blue improves the hepatopulmonary syndrome.] ''Ann Intern Med'' 133 (9):701-6. [http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00012 DOI:10.7326/0003-4819-133-9-200011070-00012] PMID: [https://pubmed.gov/11074903 11074903]</ref><ref name="pmid11497151">Jounieaux V, Leleu O, Mayeux I (2001) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11497151 Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome.] ''Intensive Care Med'' 27 (6):1103-4. PMID: [https://pubmed.gov/11497151 11497151]</ref> | *Nevertheless, norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as a standard treatment for HPS.<ref name="pmid20816858">Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20816858 Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.] ''Clin Gastroenterol Hepatol'' 8 (12):1095-8. [http://dx.doi.org/10.1016/j.cgh.2010.08.011 DOI:10.1016/j.cgh.2010.08.011] PMID: [https://pubmed.gov/20816858 20816858]</ref><ref name="pmid18779471">Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18779471 Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.] ''Arch Intern Med'' 168 (16):1820-3. [http://dx.doi.org/10.1001/archinte.168.16.1820 DOI:10.1001/archinte.168.16.1820] PMID: [https://pubmed.gov/18779471 18779471]</ref><ref name="pmid18668653">Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18668653 Pilot study of pentoxifylline in hepatopulmonary syndrome.] ''Liver Transpl'' 14 (8):1199-203. [http://dx.doi.org/10.1002/lt.21482 DOI:10.1002/lt.21482] PMID: [https://pubmed.gov/18668653 18668653]</ref><ref name="pmid12853200">Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G (2003) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12853200 Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome.] ''Lancet'' 362 (9377):43-4. [http://dx.doi.org/10.1016/S0140-6736(03)13807-X DOI:10.1016/S0140-6736(03)13807-X] PMID: [https://pubmed.gov/12853200 12853200]</ref><ref name="pmid11074903">Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C (2000) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11074903 Methylene blue improves the hepatopulmonary syndrome.] ''Ann Intern Med'' 133 (9):701-6. [http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00012 DOI:10.7326/0003-4819-133-9-200011070-00012] PMID: [https://pubmed.gov/11074903 11074903]</ref><ref name="pmid11497151">Jounieaux V, Leleu O, Mayeux I (2001) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11497151 Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome.] ''Intensive Care Med'' 27 (6):1103-4. PMID: [https://pubmed.gov/11497151 11497151]</ref> | ||
==References== | ==References== | ||
Line 20: | Line 20: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Surgery]] | ||
[[Category:Medicine]] | |||
[[Category:Pulmonology]] | |||
[[Category:Cardiology]] | |||
[[Category:Gastroentrology]] | |||
[[Category:Up-To-Date]] |
Latest revision as of 18:03, 6 September 2019
Hepatopulmonary syndrome Microchapters |
Differentiating Hepatopulmonary syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hepatopulmonary syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Hepatopulmonary syndrome medical therapy |
Risk calculators and risk factors for Hepatopulmonary syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
There is no medical treatment for hepatopulmonary syndrome. The mainstay of treatment for hepatopulmonary syndrome is surgery. Orthotopic liver transplantation is the only available treatment for patients with hepatopulmonary syndrome. Supportive therapy for hepatopulmonary syndrome includes oxygen therapy.
Medical Therapy
- There is no medical treatment for hepatopulmonary syndrome.[1]
- The mainstay of treatment for hepatopulmonary syndrome is surgery.
- Orthotopic liver transplantation is the only available treatment for patients with hepatopulmonary syndrome.
- Supportive therapy for hepatopulmonary syndrome includes oxygen therapy.
- Nevertheless, norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as a standard treatment for HPS.[8][9][10][11][12][13]
References
- ↑ Rodríguez-Roisin R, Krowka MJ (2008) Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med 358 (22):2378-87. DOI:10.1056/NEJMra0707185 PMID: 18509123
- ↑ Fallon MB, Abrams GA (2000) Pulmonary dysfunction in chronic liver disease. Hepatology 32 (4 Pt 1):859-65. DOI:10.1053/jhep.2000.7519 PMID: 11003635
- ↑ Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C et al. (2004) Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 10 (2):174-82. DOI:10.1002/lt.20016 PMID: 14762853
- ↑ Kennedy TC, Knudson RJ (1977) Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest 72 (3):305-9. DOI:10.1378/chest.72.3.305 PMID: 891282
- ↑ Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA et al. (2016) International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 100 (7):1440-52. DOI:10.1097/TP.0000000000001229 PMID: 27326810
- ↑ Krowka MJ, Dickson ER, Cortese DA (1993) Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 104 (2):515-21. DOI:10.1378/chest.104.2.515 PMID: 8101797
- ↑ Swanson KL, Wiesner RH, Krowka MJ (2005) Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 41 (5):1122-9. DOI:10.1002/hep.20658 PMID: 15828054
- ↑ Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clin Gastroenterol Hepatol 8 (12):1095-8. DOI:10.1016/j.cgh.2010.08.011 PMID: 20816858
- ↑ Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med 168 (16):1820-3. DOI:10.1001/archinte.168.16.1820 PMID: 18779471
- ↑ Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB (2008) Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 14 (8):1199-203. DOI:10.1002/lt.21482 PMID: 18668653
- ↑ Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G (2003) Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 362 (9377):43-4. DOI:10.1016/S0140-6736(03)13807-X PMID: 12853200
- ↑ Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C (2000) Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 133 (9):701-6. DOI:10.7326/0003-4819-133-9-200011070-00012 PMID: 11074903
- ↑ Jounieaux V, Leleu O, Mayeux I (2001) Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome. Intensive Care Med 27 (6):1103-4. PMID: 11497151